An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

PHASE3TerminatedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Fatty Liver
Interventions
DRUG

Rimonabant

Tablet, oral administration

DRUG

Placebo (for Rimonabant)

Tablet, oral administration

Trial Locations (24)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Cove

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Shanghai

Sanofi-Aventis Administrative Office, Bogotá

Sanofi-Aventis Administrative Office, Zagreb

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Kuala Lumpur

Sanofi-Aventis Administrative Office, México

Sanofi-Aventis Administrative Office, Makati City

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Porto Salvo

Sanofi-Aventis Administrative Office, San Juan

Sanofi-Aventis Administrative Office, Bucharest

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Geneva

Sanofi-Aventis Administrative Office, Taipei

Sanofi-Aventis Administrative Office, Guildford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY